drugset / Trial / NCT00735475

A Study to Determine the Immunogenicity and Safety Profile of CSL Limited's Influenza Virus Vaccine Compared to a US Licensed Comparator Influenza Virus Vaccine

NCT00735475

Phase 4 Completed 1268 enrolled Seqirus
RandomizedParallel-groupSingle-blindPrevention

Summary

The purpose of this study is to determine the immunogenicity and safety profile of CSL Limited's Influenza Virus Vaccine compared to a US Licensed Comparator Influenza Virus Vaccine.

Timeline

Start
2008-10
Primary completion
2009-01
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Afluria Vaccine 0.5 ml Intramuscular
Comparator Influenza Virus Vaccine Vaccine 0.5 ml Intramuscular

Indications